Breaking News

Evotec Inks Sale of Just – Evotec Biologics Toulouse Site to Sandoz

Agreement includes approximately $350 million in cash and upfront technology license fees for Evotec’s continuous manufacturing platform.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Evotec Biologics Toulouse site

Evotec SE, a drug discovery and development life science company, has signed off on the sale of the Just – Evotec Biologics Toulouse site to Sandoz AG, a global manufacturer of generic and biosimilar medicines. Under the transaction, Sandoz will acquire Just – Evotec Biologics EU plus an indefinite technology license to Evotec’s continuous manufacturing platform technology for a payment of approximately $350 million in cash. The agreement includes additional license fees and development reven...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters